• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Seven-lncRNA Program Linked to SLC7A11 Identifies Aggressive Papillary Thyroid Carcinoma Subsets

by
November 10, 2026
in Biology
Reading Time: 6 mins read
0
Seven-lncRNA Program Linked to SLC7A11 Identifies Aggressive Papillary Thyroid Carcinoma Subsets

Seven-lncRNA Program Linked to SLC7A11 Identifies Aggressive Papillary Thyroid Carcinoma Subsets

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A coordinated seven-transcript long non-coding RNA program linked to the cellular stress regulator SLC7A11 identifies an aggressive biological state and distinct immune architecture in papillary thyroid carcinoma, according to an integrated investigation published in Frontiers in Genetics. While papillary thyroid carcinoma typically follows a favorable clinical trajectory, a clinically relevant subset of patients develops persistent, recurrent, or treatment-refractory disease that anatomical staging alone fails to predict reliably. To resolve the molecular heterogeneity underlying aggressive disease, investigators from Suining Central Hospital and Chongqing University Central Hospital evaluated how cancer cells coordinate non-coding transcriptional networks to adapt to metabolic and oxidative stress. By centering their investigation on SLC7A11, a functional subunit of the system xc- cystine and glutamate antiporter that governs redox balance and nutrient vulnerability, the researchers uncovered a specialized long non-coding RNA expression signature that tracks adverse patient survival, advanced stage progression, and pronounced remodeling of the surrounding tumor immune microenvironment.

The biological rationale for focusing on SLC7A11 stems from its multifaceted and paradoxical function within cancer cell metabolism and stress adaptation. Rapidly proliferating cancer cells continuously confront oxidative stress, nutrient deprivation, and metabolic challenges generated by altered microenvironments, relying on adaptive mechanisms to sustain growth and resist therapy. SLC7A11 serves as an essential controller of cellular antioxidant defenses by importing extracellular cystine required for glutathione synthesis, thereby protecting malignant cells against lipid peroxidation and oxidative injury. However, elevated SLC7A11 activity also imposes rigid nutrient dependencies, requiring substantial quantities of glucose-derived reducing equivalents in the form of NADPH to maintain intracellular redox homeostasis. Under conditions of glucose starvation, cancer cells with elevated SLC7A11 expression accumulate toxic levels of intracellular disulfides, precipitating an atypical form of regulated cell death known as disulfidptosis, wherein aberrant disulfide bonding among actin cytoskeletal proteins triggers catastrophic F-actin network collapse. Consequently, SLC7A11 occupies an important crossroads linking cystine transport, nutrient dependency, redox fitness, and metabolic vulnerability.

Although protein-coding machinery has traditionally dominated oncologic research, long non-coding RNAs participate extensively in transcriptional and post-transcriptional gene regulation, directing vital cellular behaviors including proliferation, invasion, metastasis, and environmental adaptation. Aberrant expression of long non-coding RNAs can reshape entire regulatory cascades, yet previous investigations into thyroid carcinoma have frequently focused on isolated transcripts or assembled purely statistical prognostic classifiers without delineating the wider biological programs in which these non-coding molecules operate. Because the precise relationship between coordinated long non-coding RNA networks and SLC7A11-dependent stress adaptation remained poorly defined in papillary thyroid carcinoma, the research team hypothesized that interrogating SLC7A11-associated transcriptional networks could expose the broader biological programs governing stress survival, aggressive tumor behavior, and immune interactions, moving beyond standard clinicopathological risk stratification to characterize distinct molecular phenotypes.

To establish this network, the researchers gathered transcriptomic, clinicopathological, and somatic mutation data from The Cancer Genome Atlas thyroid carcinoma cohort, encompassing 507 primary papillary thyroid carcinoma cases. Constructing an SLC7A11-centered protein and functional interaction network via the STRING database and GeneMANIA yielded 31 functionally related genes. Pearson correlation analysis against annotated long non-coding RNAs in the thyroid cohort identified 701 candidate transcripts meeting strict predefined thresholds of absolute correlation greater than 0.55 and significance below 0.0001. The investigators then subjected these candidate transcripts to univariable Cox proportional hazards regression followed by LASSO-penalized Cox regression featuring ten-fold cross-validation to eliminate redundant features. This modeling retained seven representative long non-coding RNAs—AC107071.1, AC003086.1, AC073957.3, SPAG5-AS1, CKMT2-AS1, PRKAR1B-AS1, and GASAL1—which were weighted by their regression coefficients to calculate an individualized SLC7A11-linked lncRNA program score, designated the SLP score.

Stratifying 505 patients with complete survival data into high- and low-scoring groups around the median SLP score demonstrated that high-score tumors correlated with significantly shorter overall survival and progression-free survival. Higher scores corresponded to greater accumulation of mortality events, and multivariable Cox regression confirmed that the SLP score remained independently associated with overall survival alongside patient age after adjusting for clinicopathological variables. Time-dependent receiver operating characteristic curves yielded area-under-the-curve metrics of 0.985 at one year, 0.786 at three years, and 0.794 at five years within the TCGA-THCA cohort, while integrated nomogram calibration demonstrated agreement between predicted and observed outcomes. When stratified by anatomical stage, the SLP score did not significantly differentiate survival outcomes among patients with stage I or II disease; however, it produced marked, statistically significant survival separation among patients presenting with stage III or IV disease, indicating that the program reflects biological aggressiveness prominent in advanced disease.

Principal component analyses across four feature sets—the global transcriptome, 31 SLC7A11-related genes, 701 candidate transcripts, and the final seven-transcript signature—revealed distinct transcriptomic divergence between high- and low-SLP tumors. Functional enrichment analysis of differentially expressed genes demonstrated prominent involvement of immune and signaling cascades, including antigen processing and presentation, cytokine-receptor interactions, T-cell receptor signaling, and type II interferon transcriptional pathways. Examination of immune profiles via single-sample gene set enrichment analysis showed that high-SLP tumors paradoxically exhibited increased expression of human leukocyte antigen family genes alongside marked upregulation of negative immune checkpoint molecules, including CTLA4, PDCD1, and CD274. Correlation analysis further linked rising SLP scores to altered immune cell composition, displaying positive associations with regulatory T cells and memory B cells. Coupled with higher Tumor Immune Dysfunction and Exclusion scores, these findings describe an immune-recognizable yet functionally constrained tumor microenvironment.

Genomic characterization across 484 patients with available mutation profiles revealed that the SLP transcriptional state aligned with specific somatic landscapes. Mutation frequencies showed distinct variations in recurrent driver alterations, including BRAF, which has previously been linked to enhanced immune checkpoint expression and immunosuppressive microenvironments in papillary thyroid carcinoma. Furthermore, high-SLP tumors exhibited significantly lower tumor mutational burden compared with low-SLP counterparts, whereas higher mutational burden generally correlated with more favorable overall survival in this malignancy. Combined stratification demonstrated that patients harboring both a high SLP score and low tumor mutational burden experienced the poorest survival outcomes among all evaluated subgroups. The authors noted that because papillary thyroid carcinoma is characterized by an intrinsically low baseline mutation frequency and TCGA lacks checkpoint inhibitor treatment annotations, these findings delineate distinct genomic contexts rather than predictive markers for immunotherapy response.

To corroborate computational findings in patient tissues, the investigators evaluated candidate long non-coding RNA expression in clinical specimens collected at Chongqing University Central Hospital under institutional ethical approval. Quantitative real-time polymerase chain reaction assays performed on ten pairs of primary papillary thyroid carcinoma tumors and matched adjacent non-tumor tissues confirmed that all seven program transcripts exhibited significantly elevated expression in malignant tissues compared with normal margins. Among the validated candidates, AC107071.1, AC073957.3, and PRKAR1B-AS1 were prioritized for in vitro experimental perturbation based on their large contributions to the prognostic model, consistent tissue upregulation, and lack of prior characterization in thyroid oncology, providing an empirical foundation to test whether these transcripts actively contribute to malignant behavior or merely mirror passive transcriptional changes.

Functional evaluation in human thyroid cancer cell lines demonstrated that silencing these long non-coding RNAs directly impaired oncogenic properties and altered pharmacological stress sensitivity. Transient transfection with specific small interfering RNAs targeting AC107071.1, AC073957.3, or PRKAR1B-AS1 significantly suppressed cell proliferation and Transwell migration in TPC-1 cells compared with negative control transfections, with anti-proliferative consequences independently replicated in B-CPAP cells. Subsequent drug-response assays revealed that knocking down any of the three transcripts enhanced cell viability reduction following exposure to ML210, a selective covalent inhibitor of the downstream phospholipid hydroperoxide detoxifying enzyme GPX4. In contrast, silencing produced no comparable viability sensitization when cells were challenged with erastin, which acts upstream to inhibit system xc- cystine transport. This differential sensitivity suggests that these long non-coding RNAs may regulate downstream vulnerabilities involving membrane lipid-peroxide management or GPX4 dependency rather than upstream cystine import alone.

Despite these findings, the authors emphasized several methodological and biological limitations. The prognostic model was derived and evaluated within the TCGA-THCA cohort without a separate internal holdout or external validation cohort, meaning the calculated survival discrimination and high one-year predictive values represent apparent derivation performance requiring confirmation in independent clinical series. The experimental validation was limited to ten clinical tissue pairs, the immune microenvironment interpretations relied on bulk transcriptomic deconvolution, and CCK-8 viability assays after ML210 treatment do not establish definitive ferroptotic or disulfidptotic cell death. Direct regulation of disulfidptosis, NADPH depletion, and actin cytoskeletal collapse remains unproven and requires future glucose-starvation models and mechanistic rescue assays. Nevertheless, the study provides a comprehensive biological framework demonstrating that this seven-lncRNA program captures an aggressive, immune-remodeled tumor state linked to metabolic stress adaptation in papillary thyroid carcinoma.

Subject of Research: Identification and functional characterization of an SLC7A11-associated long non-coding RNA program in papillary thyroid carcinoma

Article Title: Integrated transcriptomic and functional analysis identifies an SLC7A11-associated lncRNA program in papillary thyroid carcinoma

Article References: Xiang, Y., Wu, L., & Zhang, P. (2026). Integrated transcriptomic and functional analysis identifies an SLC7A11-associated lncRNA program in papillary thyroid carcinoma. Frontiers in Genetics, 17, 1989287. https://doi.org/10.3389/fgene.2026.1989287

Image Credits: AI Generated

DOI: 10.3389/fgene.2026.1989287

Keywords: papillary thyroid carcinoma, SLC7A11, long non-coding RNA, metabolic stress adaptation, tumor immune microenvironment, disulfidptosis, ferroptosis, TCGA-THCA, Integrated, transcriptomic, functional, analysis

News Source: Nathaniel Bowman. (November 10, 2026). Seven-lncRNA Program Linked to SLC7A11 Identifies Aggressive Papillary Thyroid Carcinoma Subsets. Scienmag.

Tags: analysisdisulfidptosisferroptosisfunctionalintegratedlong non-coding RNAmetabolic stress adaptationPapillary thyroid carcinomaSLC7A11TCGA-THCAtranscriptomictumor-immune microenvironment
Share12Tweet7Share2ShareShareShare1

Related Posts

Iron Oxide Nanoparticles Alleviate Cadmium Stress and Accumulation in Atractylodes Lancea

Iron Oxide Nanoparticles Alleviate Cadmium Stress and Accumulation in Atractylodes Lancea

November 17, 2026
Laboratory Evolution Boosts Trehalose Production in Cupriavidus necator via Osmotic Stress Adaptation

Laboratory Evolution Boosts Trehalose Production in Cupriavidus necator via Osmotic Stress Adaptation

November 17, 2026

Inherited Mutations in Manganese Transporters Cause Distinct Metabolic Disorders

November 17, 2026

CT Findings Prompted Empirical Albendazole Treatment Despite Negative Stool Microscopy in Patient

November 17, 2026

POPULAR NEWS

  • Orthognathic Mixed Reality Templates Show Sub-Two-Millimeter Deviations in Early Scoping Review

    Orthognathic Mixed Reality Templates Show Sub-Two-Millimeter Deviations in Early Scoping Review

    29 shares
    Share 12 Tweet 7
  • Iron Oxide Nanoparticles Alleviate Cadmium Stress and Accumulation in Atractylodes Lancea

    29 shares
    Share 12 Tweet 7
  • Elevated Lipoprotein (a) Does Not Predict Long-Term Mortality After Heart Attack

    29 shares
    Share 12 Tweet 7
  • Incremental Deep Learning Reconstruction Improves High-Resolution Coronary CT Angiography Image Quality

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Sophora Flavescens Compounds Ease Colitis in Animal Models, Meta-Analysis Shows

Short-Term Endovascular Success in Peripheral Artery Disease Lacks Proven Long-Term Benefit

Longitudinal Shanghai School Study Finds Slower Myopia Progression in Later Cohorts

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.